Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF06910 Male enhanced antigen 1 (MEA1) |
Function |
May play an important role in spermatogenesis and/or testis development. |
Biological Process |
GO:0007283 spermatogenesis GO:0007548 sex differentiation GO:0008406 gonad development GO:0008584 male gonad development GO:0045137 development of primary sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046661 male sex differentiation GO:0048232 male gamete generation GO:0048608 reproductive structure development GO:0061458 reproductive system development |
Molecular Function | - |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MEA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MEA1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MEA1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MEA1 in various data sets.
|
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MEA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MEA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MEA1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MEA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MEA1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MEA1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MEA1 |
Name | male-enhanced antigen 1 |
Aliases | MEA; male-enhanced antigen; HYS; MEA-1; Male-enhanced antigen (H-Y structural gene) |
Chromosomal Location | 6p21.3-p21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MEA1 collected from DrugBank database. |
There is no record. |